BCL-2 family proteins play a central role in apoptosis regulation in mammals and in C. elegans. Mammalian cellular and viral anti-apoptosis proteins such as BCL-2 and E1B-19K interact with several cellular proteins. Some of these interacting proteins promote apoptosis and belong to the BCL-2 family. Certain BCL-2 family proapoptotic proteins such as BAX and BAK share extensive sequence homology with BCL-2. In contrast, certain pro-apoptotic proteins such as BIK and BID share a single death eector domain, BH3, with other BCL-2 family proteins. By mutational analysis, we show that one of the cellular proteins, BNIP1 (previously , that interacts with BCL-2 family anti-apoptosis proteins is a`BH3 alone' pro-apoptotic protein.
Transient transfection of BNIP1 induces a moderate level of apoptosis. Deletions of the N-terminal 32 amino acid region and the C-terminal trans-membrane domain did not signi®cantly aect pro-apoptotic activity. In contrast, deletions encompassing a region containing a motif similar to the BH3-domain abrogated the apoptotic activity. Substitution of BNIP1 BH3 domain for the corresponding sequence in BAX eciently restored the apoptotic activity of BAX, establishing the functional identity of the BH3 domain of BNIP1. The N-terminal deletions of BNIP1 (that retain the BH3 domain) enhanced the level of interaction with BCL-X L . Mutants containing the BH3 deletions were still able to heterodimerize with BCL-X L while mutants lacking both the N-terminal region and the BH3 domain were unable to heterodimerize, suggesting that BNIP1 may bind to BCL-X L via two dierent binding motifs. Oncogene (2000) 19, 2363 ± 2367.
Keywords: BNIP1; BH3 domain; apoptosis; heterodimerization Cellular and viral BCL-2 family proteins interact with several BCL-2 family pro-apoptotic proteins and certain non-BCL-2 family proteins. We have identi®ed and cloned four cellular proteins that interact with viral (E1B-19K and EBV-BHRF1) and cellular (BCL-2 and BCL-X L ) BCL-2 family anti-apoptosis proteins (Boyd et al., 1994 (Boyd et al., , 1995 . These proteins include BIK, the founding member of the`BH3-alone' pro-apoptotic proteins (Boyd et al., 1995; Chittenden et al., 1995; Han et al., 1996) , BNIP1, BNIP2 and BNIP3 (Boyd et al., 1994) . Among the latter three proteins, BNIP3 has been shown to be a member of the`BH3-alone' proteins (Yasuda et al., 1998a) . BNIP3 (Yasuda et al., 1998a; Chen et al., 1997) and its human homolog BNIP3a (Yasuda et al., 1999 , Chen et al., 1999 Matsushima et al., 1998) as well as the C. elegans homolog, ceBNIP3 (Yasuda et al., 1998b) , promote apoptosis. BNIP2 appears to be related to the signaling molecule RhoGAP (Boyd et al., 1994) and it has opposing eects on apoptosis, depending on the stimuli (X Gong and G Chinnadurai, in preparation). BNIP1 resembles other BCL-2 family proteins since it contains a characteristic C-terminal trans-membrane domain that targets it and certain heterologous proteins to mitochondria and nuclear envelope/ER regions (Boyd et al., 1994; Yasuda et al., 1998a) . In this communication, we report that BNIP1 contains a BH3 domain and promotes apoptosis. It also appears that BNIP1 may heterodimerize with BCL-X L via the BH3 domain as well as through an N-terminal motif.
Pro-apoptotic activity of BNIP1
Close examination of the sequence of BNIP1, revealed that it contains a conserved BH3-like motif between residues 114 and 119 ( Figure 1) . We, therefore, examined if BNIP1 has any apoptotic activity like other`BH3-alone' proteins. The apoptotic activity of BNIP1 was analysed by transient transfection. 293T
Oncogene (2000) cells were cotransfected with plasmids expressing wt BNIP1 or BIK (positive control) or pcDNA3 vector (negative control) along with a plasmid expressing the E. coli lacZ reporter gene. Transfected cells were stained with X-gal and the percentage of apoptotic cells was quantitated by microscopically counting the number of apoptotic blue cells from the total number of blue cells (Figure 2b ). In cells transfected with BNIP1, a consistent pro-apoptotic activity was observed. However, the activity of BNIP1 was modest when compared to BIK in the indicator cell line (293T) employed in the present study. In order to map the sequences of BNIP1 that contribute to the proapoptotic activity, we examined the activity of six dierent N-terminal deletion mutants (D20, D29, D32, D60, D69 and D119) as well as a C-terminal truncation mutant that lacks the trans-membrane domain (DTM) (Figure 2a) . Among the various mutants tested, all Nterminal mutants except D119 (in which the deletion extends to the BH3 domain) exhibited near wt level apoptotic activity (Figure 2b) . Similarly, deletion of the C-terminal trans-membrane domain also did not signi®cantly aect the pro-apoptotic activity. It is possible that the functional defect of mutant D119 may be due to the lack of the BH3 region. In order to determine the role of the BH3 domain more clearly, we constructed three internal deletion mutants of wt BNIP1, D32, and D60, each containing a deletion of aa 115 to 121 (DBH3). All three mutants lacking the BH3 domain were signi®cantly reduced in their apoptotic activity compared to the respective parental gene. Western blot analysis indicated that mutants, D32-DBH3, D60DBH3 and BNIP1DBH3 were expressed at levels comparable to that their parents (Figure 2c ). It should be noted that mutants D32DBH3, D60DBH3 and BNIP1DBH3, still retained a detectable residual apoptotic activity compared to mutant D119, raising the possibility that other regions (in addition to the BH3 domain) of BNIP1 may also contribute to the apoptotic activity.
Substitution of BNIP1 BH3 domain in BAX
To further substantiate the functional identity of the BH3 domain of BNIP1, we carried out a domain substitution study with the pro-apoptotic protein BAX (Hunter and Parslow, 1996; Zha et al. 1996) . We constructed a substitution mutant of BAX (BAX/ BNIP1BH3-9) in which a 9-amino acid region of the BH3 domain of BNIP1 was substituted for the corresponding sequence of BAX (Figure 3a) . The eect of this substitution mutation on the apoptotic activity of BAX was determined by transient transfection in 293T cells. Transfection of BAX wt resulted in 50 ± 55% of apoptotic cells while transfection of a BH3 deletion mutant (BAXDBH3) of BAX severely impaired apoptosis. Substitution of the 9-amino acid region of BNIP1 restored the proapoptotic activity of BAX (Figure 3b ). These results suggest that the BH3 domain of BNIP1 can functionally substitute for the BH3 domain of BAX.
Heterodimerization of BNIP1 with BCL-X L
We also determined the ability of various mutants of BNIP1 to heterodimerize with BCL-X L . For this purpose, the mutant proteins were prepared by in vitro transcription and translation and incubated with GST-BCL-X L fusion protein. The protein complexes were separated by chromatography on the glutathione agarose-anity matrix and analysed by SDS ± PAGE (Figure 4 ). BNIP1 wt and various BNIP1 deletion mutants (D20 ± D69) except D119 bound to BCL-X L . It is interesting to note that the N-terminal deletion mutant D20 bound to BCL-X L better than wt BNIP1 and the binding of other deletion mutants further enhanced. In contrast, BH3 deleted versions of D32 and D60 did not bind to BCL-X L (Figure 4 , right bottom panel, last two lanes). These results suggest that the N-terminal deletion mutants such as D32 and D60 heterodimerize with BCL-X L through the BH3 domain while the inability of the N-terminal deletion mutant D119 to heterodimerize with BCL-X L may be due to the lack of the BH3 domain. However, a BH3 deletion mutant of full-length BNIP1 (BNIP1DBH3) was found to bind to BCL-X L at levels comparable to that of wt BNIP1 (Figure 4 , bottom right panel). This observation suggests that BNIP1 can also bind to BCL-X L through certain sequences other than BH3. Since BH3 deleted versions of mutants D32 (BNIP1D32DBH3) and D60 (BNIP1D60DBH3) did not bind to BCL-X L at detectable levels, it appears that the second binding site of BNIP1 is located within the N-terminal 32 aa. We have shown that the cellular protein BNIP1 is à BH3-alone' pro-apoptotic protein. Deletion of the sequences corresponding to the BH3 domain reduces the apoptotic activity. Further, the BH3 domain of BNIP1 also functionally substitutes for the BH3 domain of BAX. It appears that BNIP1 may exhibit both BH3-dependent and -independent apoptotic activity as BH3 deletion mutants of BNIP1 exhibit residual apoptotic activity. Similar BH3-independent apoptotic activity has also been observed with BAX and BAK (Simonian et al., 1997 ; also see Figure 3b ). Unlike other BH3 proteins that heterodimerize with the anti-apoptotic members via the BH3 domain, BNIP1 appears to heterodimerize via the BH3 domain as well as an unde®ned motif within the N-terminal 32 aa region. It is not known if these sites function autonomously or simultaneously in the context of the full length BNIP1. However, it appears that the Nterminal sequence of BNIP1 may negatively regulate BH3-mediated heterodimerization as several deletion (D32, D60 and D69) mutants (that retain BH3) bind with BCL-X L at elevated levels compared to wt BNIP1. It has been shown that processing of the N-terminal region of BID exposes the BH3 domain (McDonnell et al., 1999; Chou et al., 1999) . Recently, certain splice variants of BNIP1 that contain the BH3 domain as well as those that do not have been identi®ed (Zhang et al., 1999) . It could be envisioned that BNIP1 and these variants may modulate apoptosis by interaction with BCL-2 family anti-apoptosis proteins in a concerted fashion.
